Brian E. Farley Sells 101,319 Shares of Entellus Medical Inc (ENTL) Stock

Entellus Medical Inc (NASDAQ:ENTL) Director Brian E. Farley sold 101,319 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $23.85, for a total value of $2,416,458.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Brian E. Farley also recently made the following trade(s):

  • On Tuesday, October 3rd, Brian E. Farley sold 6,028 shares of Entellus Medical stock. The shares were sold at an average price of $19.17, for a total value of $115,556.76.
  • On Monday, October 2nd, Brian E. Farley sold 3,972 shares of Entellus Medical stock. The shares were sold at an average price of $19.10, for a total value of $75,865.20.

Entellus Medical Inc (NASDAQ ENTL) traded down $0.25 during trading hours on Thursday, reaching $16.01. 49,600 shares of the company traded hands, compared to its average volume of 162,380. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.92 and a quick ratio of 1.71. Entellus Medical Inc has a 52-week low of $11.47 and a 52-week high of $20.34.

Several brokerages have issued reports on ENTL. Piper Jaffray Companies reissued a “buy” rating and set a $21.00 target price on shares of Entellus Medical in a research note on Tuesday, August 22nd. BidaskClub raised shares of Entellus Medical from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. Canaccord Genuity reiterated a “hold” rating and issued a $17.00 price objective on shares of Entellus Medical in a report on Tuesday, October 17th. Finally, Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Monday, October 9th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $20.40.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in Entellus Medical by 53.8% in the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after acquiring an additional 2,594 shares during the last quarter. Nationwide Fund Advisors increased its stake in shares of Entellus Medical by 61.7% during the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after purchasing an additional 2,635 shares during the last quarter. First Mercantile Trust Co. boosted its holdings in shares of Entellus Medical by 45.3% during the 2nd quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock worth $136,000 after buying an additional 2,557 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in shares of Entellus Medical by 5.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after buying an additional 573 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Entellus Medical by 145.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock worth $168,000 after buying an additional 5,605 shares during the period. 78.76% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Brian E. Farley Sells 101,319 Shares of Entellus Medical Inc (ENTL) Stock” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://ledgergazette.com/2017/12/07/brian-e-farley-sells-101319-shares-of-entellus-medical-inc-entl-stock.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply